Background: Osteoporosis (OP) is a systemic metabolic bone disease characterized by decreased bone mass and destruction of bone microstructure, which tends to result in enhanced bone fragility and related fractures. The postmenopausal osteoporosis (PMOP) has a relatively high proportion, and numerous studies reveal that estrogen-deficiency is related to the imbalance of gut microbiota (GM), impaired intestinal mucosal barrier function and enhanced inflammatory reactivity. However, the underlying mechanisms remain unclear and the existing interventions are also scarce.
Methods: In this study, we established a mouse model induced by ovariectomy (OVX) and conducted fecal microbiota transplantation (FMT) by gavage every day for 8 weeks. Subsequently, the bone mass and microarchitecture of mice were evaluated by the micro computed tomography (Micro-CT). The intestinal permeability, pro-osteoclastogenic cytokines expression, osteogenic and osteoclastic activities were detected by the immunohistological analysis, histological examination, enzyme-linked immunosorbent assay (ELISA) and western blot analysis accordingly. Additionally, the composition and abundance of GM were assessed by 16S rRNA sequencing and the fecal short chain fatty acids (SCFAs) level was measured by metabolomics.
Results: Our results demonstrated that FMT inhibited the excessive osteoclastogenesis and prevented the OVX-induced bone loss. Specifically, compared with the OVX group, FMT enhanced the expressions of tight junction proteins (zonula occludens protein 1 (ZO-1) and Occludin) and suppressed the release of pro-osteoclastogenic cytokines (tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)). Furthermore, FMT also optimized the composition and abundance of GM, and increased the fecal SCFAs level (mainly acetic acid and propionic acid).
Conclusions: Collectively, based on GM-bone axis, FMT prevented the OVX-induced bone loss by correcting the imbalance of GM, improving the SCFAs level, optimizing the intestinal permeability and suppressing the release of pro-osteoclastogenic cytokines, which may be an alternative option to serve as a promising candidate for the prevention and treatment of PMOP in the future.
The translational potential of this article: This study indicates the ingenious involvement of GM-bone axis in PMOP and the role of FMT in reshaping the status of GM and ameliorating the bone loss in OVX-induced mice. FMT might serve as a promising candidate for the prevention and treatment of PMOP in the future.
Keywords: BMD, bone mineral density; Bone loss; FMT, fecal microbiota transplantation; Fecal microbiota transplantation; GM, gut microbiota; Gut microbiota; IL-1β, interleukin-1β; KEGG, kyoto encyclopedia of genes and genomes; NMDS, non-metric multi-dimensional scaling; OP, osteoporosis; OPG, osteoprotegerin; OPLS-DA, orthogonal partial least squares discriminant analysis; OPN, osteopontin; OTU, operational taxonomic unit; OVX, ovariectomy; Ovariectomy-induced osteoporosis; PCoA, principal coordinates analysis; PMOP, postmenopausal osteoporosis; QIIME, quantitative insights into microbial ecology; RANKL, receptor activator for nuclear factor-κB ligand; RUNX2, recombinant runt related transcription factor 2; SCFAs, short chain fatty acids; Short chain fatty acids; TNF-α, tumor necrosis factor-α; TRACP5B, tartrate-resistant acid phosphatase 5B; TRAP, tartrate-resistant acid phosphatase; ZO-1, zonula occludens protein 1.
© 2022 The Authors.